Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

IBMT19101 / KITE Zuma 4 / Kristen O'Dwyer

Research Question:
Is the drug KTE-X19 safe and effective in treating acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL)?

Basic Study Information

Purpose:
The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL).

Location: University of Rochester Medical Center
Study Reference #: IBMT19101

Lead Researcher (Principal Investigator)

Lead Researcher:  Kristen O'Dwyer

Study Contact Information

Study Coordinator: Lauren Mitchell
Email: lauren_mitchell@urmc.rochester.edu

Additional Study Details

Return to Search